



ABN 11 124 426 339

Level 3, 2-4 Ross Place, South Melbourne, VIC 3205

P +61 (3) 9673 9690 F +61 (3) 9673 9699

www.purifloh.com E corporate@purifloh.com

30 November 2018

The Manager
Company Announcements Office
ASX Limited
Level 6, 20 Bridge Street
SYDNEY NSW 2000

Chairman's Address to PurifloH AGM

Good Morning Ladies and Gentlemen it gives me great pleasure to welcome you to your AGM, in what has been an exciting and eventful year for our company.

This AGM covers the 2017/18 financial year and whilst the Annual Report contains full details of that period. I'll take the opportunity to summarise that year but also to project what we hope to achieve in the forthcoming calendar year and beyond.

Firstly a comment on the markets in which we operate and our mission which is to seek to make a profound difference to many people impacted by some of the most globally recognised challenges.

It's not unreasonable to believe that every person, wherever they are located, should have access to clean water and uncontaminated air. It is also not unreasonable to feel that people presenting to a medical facility, for instance, should be comfortable that they should leave that facility without say an infection that they didn't have when they entered it. Operators of those facilities would of course share that belief too.

Antimicrobial resistance (AMR) and hospital-acquired infections (HAIs) represent one of the most significant challenges of modern medicine. AMR pathogens have the potential to jeopardise all the wonderful advances we have made in medicine and could single handedly disrupt the functioning of our healthcare system.

Our recent Licensing Agreement with Somnio Global provides PurifloH with exclusive access to their Free Radical Generator Technology – the ability to produce the highly oxidative radicals at their point of use.

The free radicals we are immediately planning to produce and commercialise – ozone and the hydroxyl ion – are amongst the most powerful oxidising agents known to man. This capability provides for many potential uses with the Company's immediate focus being on air purification, recreational water sanitation and medical sterilisation.

Their ability to destroy microbial agents makes them powerful disinfectants and could put them in the front line of protection of the hospital and medical systems. Their widespread adoption has been restricted by practical issues such as the ability to produce them at the point of use. Their short half-life does not allow for the offsite production, storage and transport of the agents, resulting in issues of cost, flexibility, reliability and consistency.

Our Research and Development partner, Somnio Global of Detroit, Michigan, have focused on solving these issues of production and deployment and have progressively advanced the technology to the stage where the production capabilities are proven and robust – supported by lengthy operating trials. We are happy calling the technology

For personal use only

proven, and it can now provide a chemical free, lower cost solution capable of driving solutions across multiple market segments.

Independent testing and verification of that Free Radical Generator via its air purification system early in 2018 were an outstanding success showing strong competitive advantages. Following those trials Purifloh commenced engagement with Original Equipment Manufacturers in the air purification industry who have also completed initial trials with great success as shown in our Powerpoint presentation released in late October. This is an important pre-cursor to further engagement with the OEM's – and to execute on our objective to have the FRG technology incorporated into their product lines.

Understandably, the, strength of the Company's IP protection and license agreement has been an important consideration for the company and for those investing in us. We are extremely fortunate, through Somnio that we have access to an experienced patent author in Doctor Pravansu Mohanty. A provisional patent was initially lodged, which has been followed by two further patent applications. These applications are a key component of a multi-faceted IP protection strategy including further patents that will ring fence the core IP and protection strategies within the production of the technology itself– protections imbedded in the power supplies and manufacturing process and techniques. Our plan is to then manufacture the FRG within Detroit – a world class manufacturing hub with many available skills and facilities – and importantly one that recognises and honours patents.

We then plan to supply the FRG to the Original Equipment Manufacturers who will design and include it within their own cabinetry – we refer to the Intel inside model of the computing industry. We plan to get to that point during 2019.

Recently we announced to the market the formal signing of the Licensing Agreement between Purifloh and Somnio which delivers exclusive worldwide rights to the technology in the fields of Air purification, Water treatment and Medical sterilisation.

And only yesterday we were pleased to be able to announce imminent in-vivo testing of the FRG technology on airborne tuberculosis in India, where one third of the 10 million new cases of TB are diagnosed each year and where TB remains a significant killer. This is a clear example of the types of specific applications where we believe the FRG technology can be used.

Throughout the year the Board was strengthened with the appointment of Steve Annear in Detroit and Lucia Cade here in Melbourne. Their biographies are impressive and they add greatly to our expertise and ability to execute our strategic plan.

Perhaps the most significant change for the Company is the recent placement to the family investment company of Mr Bill Parfet, and his decision to join the Board. This is truly a phenomenal appointment by a person who has been managing and on the Boards of many substantial companies such as Upjohn Pharmaceuticals, Pharmacia, Stryker and Monsanto. Whilst he is following his investment, I am sure he has not taken this step lightly, and a clear endorsement of his belief in the technology.

Rest assured - he employs a sophisticated team of professionals who conducted rigorous due diligence on both the science and commercial potential of Purifloh before investing. We warmly welcome Mr Parfet to the company and Board of Purifloh. Your company is far stronger for his involvement.

As a result, after over 4 years of hard work and collaboration with Somnio Global we are confident that we have now a technology that has a very strong competitive advantage in the markets we are targeting, very strong financial backing, an executed R&D and Licensing Agreement, and a Board with the knowledge, experience and the capability to commercialise a series of globally significant technologies.

In the short term our immediate focus will be to add the resources necessary to commercialise the technology with the appointment of a Chief Executive Officer and Business Development team in the United States. Establishing the base of our operations in the US is calculated in that it is not only the largest market in the world for our products, but also is the headquarters of the main OEM's and Detroit itself is a long established centre of engineering and manufacturing.

With air purification trials already underway with Original Equipment Manufacturers (OEMs) we aim to complete a Licensing Agreement in the first half of 2019. We also expect to complete field trials of the Recreational Water System at that time. The commencement of the manufacture of FRG Core Technology and field trials of the Surface Sterilisation System in 2019 should lead to the commencement of sales in Air and Sterilisation Systems in 2020.

It has been a particularly eventful 6 months for the company and one that we feel sets PuriflOH up for the very long term in not only providing practical and usable solutions to some of the critical issues faced around the globe, but also for shareholders to participate in the fruits of that success.

We have an exciting period ahead.

I thank you for your support, we will continue to provide shareholders with regular updates as we execute on our plan, and we look forward to a long and successful partnership with you.

Thank you.

Steve Morris
Chairman
Level 3, 2-4/Ross Place
South Melbourne 3205
M: +61 407 998 354
E: simon.lill@purifloh.com.au



For personal use only